Seven patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Mar 2042. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Mar 2042
Next term end
5
Patent families
When these terms end
Each bar runs from grant to computed term end. 2024 to 2044.
US 12,257,318
Polynucleotide Compositions, Related Formulations, and Methods of Use Thereof
no later than Mar 23, 2042
20282032203620402044
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
22 pending applications: term is not computable until grant.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 4 largest of its 5 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Lipid Nanoparticle Compositions and Uses Thereof (2024) | 3 in force | to Dec 2043 |
| Lipid Nanoparticle Compositions and Uses Thereof (2024) | 1 in force | to Feb 2044 |
| Polynucleotide Compositions, Related Formulations, and Methods of Use Thereof | 1 in force | to Mar 2042 |
| Compositions and Methods for Targeted Delivery to Cells | 1 in force | to Mar 2042 |
Patents held now
Soonest term end first.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,121,610 | Compositions and Methods for Targeted Delivery to Cells In force · Low confidence | In force | Low confidence | |
| US 12,257,318 | Polynucleotide Compositions, Related Formulations, and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 12,133,923 | Lipid Nanoparticle Compositions and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 12,337,068 | Lipid Nanoparticle Compositions and Uses Thereof In force · Low confidence | In force | Low confidence | |
| US 12,582,611 | Lipid Nanoparticle Compositions and Uses Thereof In force · Low confidence | In force | Low confidence | |
| US 12,364,773 | Lipid Nanoparticle Compositions and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,553,042 | Method for Quantifying an Amount of Capped Messenger RNA In force · High confidence | In force | High confidence |
Also on record, not counted in the 7: 22 applications pending · 5 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
3 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed
4 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.